Literature DB >> 10602663

Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms.

M L Rodrigues1, C S Alviano, L R Travassos.   

Abstract

Cryptococcus neoformans is the causative agent of cryptococcosis and cryptococcal meningitis, which are serious pathological conditions affecting up to 10% of patients with AIDS. Mechanisms of pathogenicity of C. neoformans and the host defenses against this fungus are reviewed, incorporating recent data and perspectives.

Entities:  

Mesh：

Year:  1999        PMID： 10602663     DOI： 10.1016/s1286-4579(99)80025-2

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  25 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter; Débora L Oliveira; Susana Frases; Kildare Miranda; Oscar Zaragoza; Mauricio Alvarez; Antonio Nakouzi; Marta Feldmesser; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2006-11-17

3.  Fungal Extracellular Vesicles in Pathophysiology.

Authors:  Donovan Garcia-Ceron; Mark R Bleackley; Marilyn A Anderson
Journal:  Subcell Biochem       Date:  2021

Review 4.  Virulence mechanisms and Cryptococcus neoformans pathogenesis.

Authors:  J Andrew Alspaugh
Journal:  Fungal Genet Biol       Date:  2014-09-23       Impact factor: 3.495

5.  Functional cloning and characterization of a UDP- glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis.

Authors:  M Bar-Peled; C L Griffith; T L Doering
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

7.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.

Authors:  Priscila C Albuquerque; Fernanda L Fonseca; Fabianno F Dutra; Marcelo T Bozza; Susana Frases; Arturo Casadevall; Marcio L Rodrigues
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

10.  Atypical biosynthetic properties of a Delta 12/nu+3 desaturase from the model basidiomycete Phanerochaete chrysosporium.

Authors:  Robert E Minto; Brenda J Blacklock; Hina Younus; Andrew C Pratt
Journal:  Appl Environ Microbiol       Date:  2008-12-16       Impact factor: 4.792
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.